NASD · Healthcare · Medical Devices · USA
Co-Diagnostics Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.
Co-Diagnostics develops and sells reagents for PCR diagnostic tests that detect nucleic acid molecules for infectious diseases. Using proprietary Co-Primers technology, the company has obtained regulatory approvals in multiple countries for tests detecting COVID-19, influenza, tuberculosis, hepatitis, and other pathogens for clinical laboratory use. The company is developing the Co-Dx PCR platform for point-of-care testing.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Co-Diagnostics Inc stock.
Undervalued: intrinsic value $0.93 per share, market price $0.20, margin of safety 78.5% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $0.93; the price of $0.20 is 78% below that value.
All 140 Medical Devices stocks
CODX is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.93; the price of $0.20 is 78% below that value.
$0.93 per share (as of the 2026-11-17 close), against a market price of $0.20. That is a margin of safety of 78.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.